There are potentially 10 different coronavirus vaccines that could be available by the middle of next year if regulatory approval and patent protections go through.
An international consortium of pharmaceutical companies said vaccines by Pfizer, BioNtech, Moderna and AstraZeneca have shown promise in clinical trials and other firms are expected to show similar results, Reuters reported.
“So far 3 we have 3 out of 3 were hits. I would expect that we will see something similar with Johnson & Johnson, I would expect that we would see similar positive results with Novavax, and many others, Sanofi Pasteur, GSK are in there, Merck,” Thomas Cueni, director of the International Federation of Pharmaceutical Manufacturers and Associations. “We will hopefully by the next summer have probably 10 vaccines which have proven their value. But all of them really need to be submitted by rigorous scientific scrutiny by the regulators.”
A vaccine offered by AstraZeneca has been clouded in controversy this week after some mistakes were found in the dosing of test subjects and might have to undergo more trials before it goes for regulatory approval.
The first patients in the U.S. could receive immunizations for the coronavirus Dec. 12, health officials said.
The Food and Drug Administration advisory committee meets Dec. 10 and if Pfizer’s request for emergency use authorization is approved, its vaccine could begin shipment within 24 hours.
More coronavirus pandemic coverage:
Cox Media Group